Trial Profile
Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Pulmonary hypertension
- Focus Registrational; Therapeutic Use
- Acronyms FUTURE 4
- Sponsors Actelion Pharmaceuticals
- 16 Apr 2014 New trial record